Riitta Lassila
Riitta Lassila is an expert in Hematology at Helsinki University Hospital (Finland). As of October 2026, ScienceLeadR ranks Riitta Lassila in the top 1% of experts worldwide for Embolism and Thrombosis, and in the top 1% of experts in Finland for Hemophilia A. Riitta Lassila has authored 320 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 1 of them ongoing. SLR score: 1,021 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Cardiology - Oncology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1988 - 2026
Number : 320
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Thrombotic rates in individuals with inherited bleeding disorders treated with concentrate or bispecific antibody. Fifteen-year EUHASS data. PMID 42829087 — hemorrhage, hemophilia a, blood coagulation factors, therapeutics, thrombosis | J Thromb Haemost | 2026 | 0 |
| Personalized Treatment of Hemophilia: Matching Therapies to Patient Needs in a Rapidly Evolving Landscape. PMID 42786360 — hemorrhage, pharmaceutical preparations, drug therapy, hemophilia a, therapeutics | Drugs | 2026 | 0 |
| Post-operative venous thromboembolism in advanced epithelial ovarian cancer: risk factors, tumor gene expression, and survival. PMID 42442219 — cells, genes, thromboembolism, factor viii, erythrocytes, blood, incidence, erythrocyte transfusion, ovary, neoplasms, biomarkers, ovarian neoplasms, risk factors, blood cells, venous thromboembolism, tissues, carcinoma, ovarian epithelial, gene expression | Int J Gynecol Cancer | 2026 | 0 |
| Von Willebrand disease: A century of progress. PMID 42405180 — hemorrhage, genetics, von willebrand diseases, hemophilia a, diagnosis, therapeutics | Res Pract Thromb Haemost | 2026 | 0 |
| Therapeutic Strategies Combining Antiplatelet With Anticoagulant Actions: Heparin Proteoglycan Mimetic APAC as a Model. PMID 42206369 — anticoagulants, safety, hemorrhage, proteoglycans, fibrinolytic agents, heparin, vascular diseases, reperfusion injury, endothelial cells, atherosclerosis, therapeutics, thrombosis, blood platelets | Arterioscler Thromb Vasc Biol | 2026 | 0 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Convalescent Plasma in the Treatment of Covid 19 NCT04730401 — safety, covid-19, therapeutics, plasma | Phase 2 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map